FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antigen binding molecule (ABM) which specifically binds with membrane-bound human carcinoembyronic antigen (CEA). Also disclosed is an ABM-coding polynucleotide, a coded ABM expression vector, a host cell for ABM expression and a composition for treating cancer, for which abnormal CEA expression is typical. The invention discloses methods of inducing cell lysis of tumour tissue, a disease diagnosis method, a method of prolonging life, a method of inducing tumour regression, a method of treating and a method of inducing CEA-mediated tumour cell adhesion.
EFFECT: invention is characterised by specific binding with membrane-bound human carcinoembyronic antigen (CEA), which enables to efficiently treat diseases associated with CEA polypeptide expression.
31 cl, 16 dwg, 11 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| MODIFIED ANTIGEN-BINDING MOLECULES WITH CHANGED CELL SIGNAL ACTIVITY | 2006 |
|
RU2547931C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| ANTIGEN-BINDING MOLECULES, WHICH BIND EGFR, VECTORS CODING THEM AND USE THEREOF | 2013 |
|
RU2610688C2 |
| THYMIC STROMAL LYMPHOPOIETIN RECEPTOR ANTIBODIES | 2007 |
|
RU2486202C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2663123C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
